Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Apellis Pharmaceuticals Inc shares valued at $702,057 were sold by Dunlop A. Sinclair on Sep 30 ’25. At $22.58 per share, Dunlop A. Sinclair sold 31,092 shares. The insider’s holdings dropped to 33,979 shares worth approximately $0.85 million following the completion of this transaction.
Also, Dunlop A. Sinclair sold 31,092 shares, netting a total of over 713,561 in proceeds. Following the sale of shares at $22.95 each, the insider now holds 68,908 shares.
Before that, Dunlop A. Sinclair had added 93,276 shares to its account. In a trade valued at $2,140,917, the Director bought Apellis Pharmaceuticals Inc shares for $22.95 each.
As published in a research note from Goldman on September 26, 2025, Apellis Pharmaceuticals Inc [APLS] has been rated down from a Neutral to a Sell and the price target has been revised to $18. Analysts at Raymond James downgraded the stock from ‘”a Strong buy”‘ to ‘”an Outperform”‘ outlook in a report released in early May. As of May 09, 2025, BofA Securities has decreased its “Buy” rating to a “Neutral” for APLS. Earlier on April 29, 2025, Cantor Fitzgerald initiated its rating. Their recommendation was “an Overweight” for APLS stock.
Analyzing APLS Stock Performance
On last trading session, Apellis Pharmaceuticals Inc [NASDAQ: APLS] plunged -1.15% to $24.92. The stock’s lowest price that day was $24.44, but it reached a high of $25.41 in the same session. During the last five days, there has been a surge of approximately 7.88%. Over the course of the year, Apellis Pharmaceuticals Inc shares have dropped approximately -9.41%. Shares of the company reached a 52-week high of $35.57 on 01/07/25 and a 52-week low of $16.10 on 05/15/25.
Support And Resistance Levels for Apellis Pharmaceuticals Inc (APLS)
According to the 24-hour chart, there is a support level at 24.44, which, if violated, would cause prices to drop to 23.95. In the upper region, resistance lies at 25.41. The next price resistance is at 25.89. RSI (Relative Strength Index) is 56.12 on the 14-day chart, showing neutral technical sentiment.
Is Apellis Pharmaceuticals Inc subject to short interest?
Stocks of Apellis Pharmaceuticals Inc saw a sharp rise in short interest on 2025-09-15 jumping by 1.48 million shares to 21.76 million. Data from Yahoo Finance shows that the short interest on 2025-08-15 was 20.27 million shares. A jump of 6.82% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.29 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.29.
Which companies own the most shares of Apellis Pharmaceuticals Inc (APLS)?
In terms of Apellis Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 20 in the next 12 months, down nearly -20.67% from the previous closing price of $25.21. Analysts anticipate Apellis Pharmaceuticals Inc stock to reach 22 by 2025, with the lowest price target being 18. In spite of this, 14 analysts ranked Apellis Pharmaceuticals Inc stock as Buy at the end of 2025. On December 17, 2024, Goldman assigned a price target of “a Neutral” to the stock and downgraded coverage with a $36.
